Much has been written about cytokines over the last decade in terms of various ways of employing them systematically as cancer therapeutics.

There has been little success reported, however, beyond a small number of patients receiving high dose IL-2 in certain situations such as melanoma and renal cell carcinoma.

What if we take an orthoganal approach to the problem and explore different ways of delivering the desired effects?

Does this change the outcomes, and with it, our thinking?

To learn more from our latest oncology expert interview and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by